Results 51 to 60 of about 1,925 (192)

Respiratory Syncytial Virus (RSV): A Comprehensive Overview From Basic Biology to Clinical Prevention and Control

Medicinal Research Reviews, Volume 46, Issue 3, Page 672-712, May 2026.
ABSTRACT Respiratory syncytial virus (RSV) is a common virus that causes respiratory infections, posing a serious threat, particularly to infants, the elderly, and individuals with compromised immune systems. As the leading cause of lower respiratory tract infections (LRTIs) in infants, RSV is responsible for millions of cases worldwide each year.
Jie Shi, Xiya Huang, Chunjun Ye, Yishan Lu, Yanyan Liu, Yuquan Wei, Xiawei Wei   +6 more
wiley   +1 more source

Incidence of Respiratory Syncytial Virus Infection Among Patients Aged Less Than 2 Years: A Retrospective Study From an Italian Southern Region in Years 2018–2023

Influenza and Other Respiratory Viruses, Volume 20, Issue 5, May 2026.
ABSTRACT Introduction Respiratory syncytial virus (RSV) is one of the most common viruses infecting nearly all children worldwide within the first 2 years of life, requiring hospitalization for over 80% of cases in infants under the age of 1. The aim of this study was to evaluate the epidemiological impact of RSV infections on hospital admissions among
Giuseppe Di Martino, Pamela Di Giovanni, Federica Vaccaro, Francesca Romana Cascavilla, Carla Di Marzio, Livia Tognaccini, Edoardo Trebbi, Teresa Aita, Ferdinando Romano, Tommaso Staniscia   +9 more
wiley   +1 more source

Impact du nirsevimab sur les infections pédiatriques au VRS en Belgique en 2024-2025 : une analyse des données de surveillance sentinelle de routine de Sciensano

Nous estimons que 35 à 45 % des hospitalisations ont été évitées grâce à l’introduction du nirsevimab. Nous estimons que l’introduction du nirsevimab a permis de diminuer de 35 à 45 % les hospitalisations liées à une infection au VRS chez les enfants de ...
T. Braeye, A. Lajot, L. Cornelissen, L. De Mot, S. Hanoteaux, Y. Dockx, B.E.L.S.A.R.I.N.E.Tresearch group, S. Denayer, Y. Lafort, I. Van Evercooren, M. Fonnesu, Y. Dupont, K. Blot, M. Vandromme, P. Mpakaniye, M.U. Paz   +15 more
core   +1 more source

Nirsevimab (▼Beyfortus®): un nuevo anticuerpo monoclonal para la profilaxis frente al virus respiratorio sincitial [PDF]

, 2023
Farmacologia; Medicaments; Virus respiratori sincicialFarmacología; Medicamentos; Virus respiratorio sincicialPharmacology; Medicines; Respiratory syncytial virusAquest article tracta del medicament nirsevimab, un nou anticòs monoclonal que actua ...

core  

Expanded Genomic Surveillance and Seasonal Comparisons of Human Respiratory Syncytial Virus Infections in Minnesota, USA, 2023–2025

Influenza and Other Respiratory Viruses, Volume 20, Issue 5, May 2026.
ABSTRACT Background Human respiratory syncytial virus (HRSV) imposes a substantial burden in the United States. The use of whole‐genome sequencing (WGS) for public health surveillance of HRSV lags that for other viral pathogens. The objective of this study was to expand the scope and depth of WGS‐based surveillance of HRSV in Minnesota, USA.
Daniel Evans, Henry Kunerth, Erica Mumm, Matthew Plumb, Laura Bohnker‐Voels, Sarah Bistodeau, Scott A. Cunningham, Jordan Davis, Karen Martin, Kathryn Como‐Sabetti, Sarah Namugenyi, Xiong Wang, Ruth Lynfield, Anna Strain, Sara Vetter   +14 more
wiley   +1 more source

Impact van nirsevimab op pediatrische RSV-infecties in België in 2024-2025. Een analyse van de routine sentinel-surveillancegegevens van Sciensano

We schatten dat 35 tot 45% van de ziekenhuisopnames is voorkomen door de introductie van nirsevimab. We schatten dat de introductie van nirsevimab heeft geleid tot 35-45% minder ziekenhuisopnames voor een RSV-infectie bij kinderen jonger dan 5 jaar.
T. Braeye, A. Lajot, L. Cornelissen, L. De Mot, S. Hanoteaux, Y. Dockx, B.E.L.S.A.R.I.N.E.Tresearch group, S. Denayer, Y. Lafort, I. Van Evercooren, M. Fonnesu, Y. Dupont, K. Blot, M. Vandromme, P. Mpakaniye, M.U. Paz   +15 more
core   +1 more source

Nirsevimab in the prevention of respiratory syncytial virus lower respiratory tract disease: a profile of its use

, 2023
   Declarations Funding The preparation of this review was not supported by any external funding. Authorship and conflict of interest M. Shirley is a salaried employee of Adis International Ltd/Springer Nature and declare(s) no relevant conflicts of ...
Matt Shirley (7340599)
core   +1 more source

Population Pharmacokinetics of Clesrovimab in Preterm and Full‐Term Infants

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 1036-1046, April 2026.
Clesrovimab is a half‐life extended monoclonal antibody targeting the respiratory syncytial virus fusion protein. Three studies (phase Ib/IIa [MK‐1654‐002], phase IIb/III [CLEVER], and phase III [SMART]) were conducted to evaluate the efficacy, safety, and pharmacokinetics (PK) of clesrovimab in infants.
Ziheng Hu, Farina Hellmann, Xiaowei Zang, Nele Plock, Keyur Parmar, Radha A. Railkar, S. Y. Amy Cheung, Brian M. Maas, Ferdous Gheyas   +8 more
wiley   +1 more source

Effectiveness of nirsevimab immunization against RSV infection in preterm infants: a systematic review and meta-analysis

Frontiers in Immunology
BackgroundRespiratory Syncytial Virus (RSV) is one of the primary pathogen responsible for severe lower respiratory tract infections in preterm infants, placing a significant burden on patients, their families, and society.
Xiaopeng Wang, Xiaopeng Wang, Xiaopeng Wang, Li Kong, Li Kong, Li Kong, Xueou Liu, Panpan Wu, Panpan Wu, Panpan Wu, Lulu Zhang, Lulu Zhang, Lulu Zhang, Fangrui Ding, Fangrui Ding, Fangrui Ding   +15 more
doaj   +1 more source

Maternal RSV vaccination for infant protection: A systematic review and meta‐analysis of phase 3 trials with an integrated economic evaluation

International Journal of Gynecology &Obstetrics, Volume 173, Issue 1, Page 63-73, April 2026.
Abstract Background Respiratory syncytial virus (RSV) is a leading cause of hospitalization and mortality in early infancy. Maternal immunization offers a preventive strategy, but uncertainties regarding safety and economic value have limited its implementation.
Johnatan Torres‐Torres, Lourdes Rojas‐Zepeda, José Rafael Villafan‐Bernal, Raigam Martinez‐Portilla, Salvador Espino‐y‐Sosa, Pablo Cerda‐Flores, Elsa Romelia Moreno‐Verduzco, Irma Eloisa Monroy‐Muñoz, Ameyran Yolanda Gonzalez‐Guerrero, Juan Mario Solis‐Paredes, Javier Perez Duran   +10 more
wiley   +1 more source